AtriCure (ATRC Quick QuoteATRC - Free Report) reported $153.6 million in revenue for the quarter ended June 2026, representing a year-over-year increase of 12.8%. EPS of $0.18 for the same period compares to -$0.02 a year ago.

The reported revenue represents a surprise of +1.39% over the Zacks Consensus Estimate of $151.5 million. With the consensus EPS estimate being $0.03, the EPS surprise was +500%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how AtriCure performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• United States Revenue- Pain management: $27.06 million versus the three-analyst average estimate of $24.91 million. The reported number represents a year-over-year change of +27.8%.
• International Revenue- Pain management: $2.38 million versus $2.56 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +17.1% change.
• United States Revenue- Total ablation ( Open ablation+Minimally invasive ablation+Pain management): $73.97 million compared to the $71.95 million average estimate based on three analysts. The reported number represents a change of +13% year over year.
• International Revenue- Total ablation ( Open ablation+Minimally invasive ablation+Pain management): $15.64 million versus $16.12 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +6% change.
• United States Revenue- Total: $125.59 million versus the three-analyst average estimate of $122.88 million. The reported number represents a year-over-year change of +13.6%.
• International Revenue- Appendage management: $12.37 million compared to the $12.57 million average estimate based on three analysts. The reported number represents a change of +14.5% year over year.
• United States Revenue- Open ablation: $40.89 million compared to the $40.9 million average estimate based on three analysts. The reported number represents a change of +12.1% year over year.
• International Revenue- Open ablation: $11.24 million compared to the $11.39 million average estimate based on three analysts. The reported number represents a change of +8.6% year over year.
• United States Revenue- Minimally invasive ablation: $6.03 million versus $6.14 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -23.1% change.
• International Revenue- Minimally invasive ablation: $2.02 million versus $2.17 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -14.8% change.
• United States Revenue- Appendage management: $51.61 million versus $50.93 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +14.4% change.
• International Revenue- Total: $28.02 million versus the three-analyst average estimate of $28.7 million. The reported number represents a year-over-year change of +9.6%.

View all Key Company Metrics for AtriCure here>>>

Shares of AtriCure have returned +18.5% over the past month versus the Zacks S&P 500 composite's +0.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.